1. Home
  2. FA vs AGIO Comparison

FA vs AGIO Comparison

Compare FA & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Advantage Corporation

FA

First Advantage Corporation

HOLD

Current Price

$12.10

Market Cap

1.7B

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$27.49

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FA
AGIO
Founded
2003
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
FA
AGIO
Price
$12.10
$27.49
Analyst Decision
Hold
Buy
Analyst Count
3
8
Target Price
$15.50
$37.63
AVG Volume (30 Days)
1.5M
791.9K
Earning Date
01-01-0001
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
72.97
N/A
EPS
N/A
N/A
Revenue
$1,574,389,000.00
$43,011,000.00
Revenue This Year
$8.11
$75.68
Revenue Next Year
$7.34
$167.63
P/E Ratio
N/A
N/A
Revenue Growth
83.02
N/A
52 Week Low
$8.82
$22.24
52 Week High
$19.01
$46.00

Technical Indicators

Market Signals
Indicator
FA
AGIO
Relative Strength Index (RSI) 54.07 42.16
Support Level $8.82 $26.40
Resistance Level $14.56 $29.49
Average True Range (ATR) 0.65 1.18
MACD 0.40 -0.19
Stochastic Oscillator 82.45 14.64

Price Performance

Historical Comparison
FA
AGIO

About FA First Advantage Corporation

First Advantage Corp is a provider of global software and data in the Human Resources technology industry. The company leverages proprietary technology and AI across its platforms, data, and APIs to deliver comprehensive background screening, digital identity, and verification solutions driven by innovation, automation, and customer success. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. Maximum revenue is generated from the First Advantage Americas segment. The group serves customers in over 200 countries and territories, modernising hiring and onboarding on a global scale.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: